Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial.
Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, Hamburger J, Rutsch W, Kaiser C, Whitbourn R, Camenzind E, Meredith I, Reeves F, Nienaber C, Benit E, Disco C, Koglin J, Colombo A; TAXUS II Study Group. Serruys PW, et al. Among authors: meredith i. Circulation. 2004 Feb 10;109(5):627-33. doi: 10.1161/01.CIR.0000112566.87022.32. Circulation. 2004. PMID: 14769685 Clinical Trial.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Serruys PW, et al. Among authors: meredith i. Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098436
6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Smits P, Koolen J, Meredith I, Li D, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Diletti R, et al. Among authors: meredith i. J Am Coll Cardiol. 2011 Jul 12;58(3):258-64. doi: 10.1016/j.jacc.2011.02.052. J Am Coll Cardiol. 2011. PMID: 21737016 Free article.
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Serruys PW, et al. Among authors: meredith i. J Am Coll Cardiol. 2011 Oct 4;58(15):1578-88. doi: 10.1016/j.jacc.2011.05.050. J Am Coll Cardiol. 2011. PMID: 21958884 Free article. Clinical Trial.
Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S, Gomez-Lara J, Garcia-Garcia HM, Heo JH, Farooq V, van Geuns RJ, Chevalier B, Windecker S, McClean D, Thuesen L, Whitbourn R, Meredith I, Dorange C, Veldhof S, Rapoza R, Ormiston JA, Serruys PW. Brugaletta S, et al. Among authors: meredith i. Int J Cardiovasc Imaging. 2012 Aug;28(6):1307-14. doi: 10.1007/s10554-011-9981-4. Epub 2011 Nov 23. Int J Cardiovasc Imaging. 2012. PMID: 22108907 Free PMC article. Clinical Trial.
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S, Gomez-Lara J, Serruys PW, Farooq V, van Geuns RJ, Thuesen L, Dudek D, Koolen J, Chevalier B, McClean D, Windecker S, Smits PC, de Bruyne B, Whitbourn R, Meredith I, van Domburg RT, Sihan K, de Winter S, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM, Ormiston JA, Bruining N. Brugaletta S, et al. Among authors: meredith i. JACC Cardiovasc Interv. 2011 Dec;4(12):1281-9. doi: 10.1016/j.jcin.2011.08.014. JACC Cardiovasc Interv. 2011. PMID: 22192369 Free article. Clinical Trial.
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Diletti R, et al. Among authors: meredith i. Heart. 2013 Jan;99(2):98-105. doi: 10.1136/heartjnl-2012-302598. Epub 2012 Oct 31. Heart. 2013. PMID: 23118346 Clinical Trial.
Short- and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer – results from the RESOLUTE trial –.
Waseda K, Ako J, Yamasaki M, Koizumi T, Ormiston J, Worthley SG, Whitbourn RJ, Walters DL, Honda Y, Meredith IT, Fitzgerald PJ; RESOLUTE Trial Investigators. Waseda K, et al. Circ J. 2010 Oct;74(10):2097-102. doi: 10.1253/circj.cj-10-0063. Epub 2010 Aug 3. Circ J. 2010. PMID: 20689221 Free article. Clinical Trial.
Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B investigators. Onuma Y, et al. Among authors: meredith i. Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12. doi: 10.1002/ccd.22864. Epub 2011 Mar 16. Catheter Cardiovasc Interv. 2011. PMID: 21413120 Clinical Trial.
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. Ormiston JA, et al. Among authors: meredith i. Circ Cardiovasc Interv. 2012 Oct;5(5):620-32. doi: 10.1161/CIRCINTERVENTIONS.112.971549. Epub 2012 Oct 9. Circ Cardiovasc Interv. 2012. PMID: 23048057 Clinical Trial.
368 results